Results 71 to 80 of about 15,465 (199)

Outcomes in COVID-19 Patients with Pneumonia Treated with High-Flow Oxygen Therapy and Baricitinib—Retrospective Single-Center Study

Life, 2023
Background. The aim of the study was to assess the effect of baricitinib on 28-day all-cause mortality and the progression of respiratory failure in patients needing transfer to the intensive care unit (ICU) with COVID-19 pneumonia treated with high-flow
Dušanka Obradović, Milica Popović, Maja Banjac, Jelena Bulajić, Vladimir Đurović, Ivana Urošević, Aleksandra Milovančev   +6 more
doaj   +1 more source

Updated COVID‐19 Vaccines and Health Outcomes in Patients With Autoimmune Rheumatic Conditions

Arthritis &Rheumatology, EarlyView.
Objective We aimed to assess the association between COVID‐19 vaccination status and COVID‐19‐related hospital admissions, need for mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and death in people with autoimmune rheumatic conditions. Methods We conducted a retrospective cohort study using National Clinical Cohort Collaborative
Lesley E. Jackson, A. Jerrod Anzalone, Kenneth G. Saag, Rahima Begum, AKM F. Rahman, Namrata Singh, Kaleb Michaud, Jasvinder A. Singh, Rena C. Patel, Maria I. Danila, on behalf of the National Clinical Cohort Collaborative Consortium, Adam B. Wilcox, Adam M. Lee, Alexis Graves, Alfred (Jerrod) Anzalone, Amin Manna, Amit Saha, Amy Olex, Andrea Zhou, Andrew E. Williams, Andrew M. Southerland, Andrew T. Girvin, Anita Walden, Anjali Sharathkumar, Benjamin Amor, Benjamin Bates, Brian Hendricks, Brijesh Patel, G. Caleb Alexander, Carolyn T. Bramante, Cavin Ward‐Caviness, Charisse Madlock‐Brown, Christine Suver, Christopher G. Chute, Christopher Dillon, Chunlei Wu, Clare Schmitt, Cliff Takemoto, Dan Housman, Davera Gabriel, David A. Eichmann, Diego Mazzotti, Donald E. Brown, Eilis Boudreau, Elaine L. Hill, Emily Carlson Marti, Emily R. Pfaff, Evan French, Farrukh M. Koraishy, Federico Mariona, Fred Prior, George Sokos, Greg Martin, Harold P. Lehmann, Heidi Spratt, Hemalkumar B. Mehta, J. W. Awori Hayanga, Jami Pincavitch, Jaylyn Clark, Jeremy Richard Harper, Jessica Yasmine Islam, Jin Ge, Joel Gagnier, Johanna J. Loomba, John B. Buse, Jomol Mathew, Joni L. Rutter, Julie A. McMurry, Justin Guinney, Justin Starren, Karen Crowley, Katie Rebecca Bradwell, Kellie M. Walters, Ken Wilkins, Kenneth R. Gersing, Kenrick Cato, Kimberly Murray, Kristin Kostka, Lavance Northington, Lee Pyles, Lesley Cottrell, Lili M. Portilla, Mariam Deacy, Mark M. Bissell, Marshall Clark, Mary Emmett, Matvey B. Palchuk, Melissa A. Haendel, Meredith Adams, Meredith Temple‐O'Connor, Michael G. Kurilla, Michele Morris, Nasia Safdar, Nicole Garbarini, Noha Sharafeldin, Ofer Sadan, Patricia A. Francis, Penny Wung Burgoon, Philip R. O. Payne, Randeep Jawa, Rebecca Erwin‐Cohen, Rena C. Patel, Richard A. Moffitt, Richard L. Zhu, Rishikesan Kamaleswaran, Robert Hurley, Robert T. Miller, Saiju Pyarajan, Sam G. Michael, Samuel Bozzette, Sandeep K. Mallipattu, Satyanarayana Vedula, Scott Chapman, Shawn T. O'Neil, Soko Setoguchi, Stephanie S. Hong, Steven G. Johnson, Tellen D. Bennett, Tiffany J. Callahan, Umit Topaloglu, Valery Gordon, Vignesh Subbian, Warren A. Kibbe, Wenndy Hernandez, Will Beasley, Will Cooper, William Hillegass, Xiaohan Tanner Zhang   +127 more
wiley   +1 more source

AMETHYST: A Retrospective Cohort Study of Treatment Patterns and Outcomes in Patients With Glucocorticoid‐Refractory Macrophage Activation Syndrome Complicating Still's Disease

Arthritis &Rheumatology, EarlyView.
Objective Information is limited on the natural history and current treatment patterns in macrophage activation syndrome (MAS), a life‐threatening hyperinflammatory syndrome complicating Still's disease (systemic juvenile idiopathic arthritis [sJIA] and adult‐onset Still's disease [AOSD]).
Alexei Grom, Jordi Antón, Edward M. Behrens, Corey Best, Norbert Blank, Josefin Blomkvist, Scott W. Canna, Sonia Carriquí, Shanmuganathan Chandrakasan, Andrew Danquah, Ngoc‐Bao Duong, Brian D. Jamieson, Paivi Miettunen, Abiola Oladapo, Sampath Prahalad, Pierre Quartier, Grant Schulert, Anna Stoltenberg, Uwe Ullmann, Erika Van Nieuwenhove, Sebastiaan J. Vastert, Fabrizio De Benedetti   +21 more
wiley   +1 more source

A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients

Trials, 2023
Background Primary Sjogren’s syndrome (pSS) is a systemic autoimmune disease involving multiple organ systems. The Janus kinase/signal transduction and activator of transcription (JAK/STAT) signaling pathway is a key pathway involving the pathogenesis of
Wei Bai, Fan Yang, Huji Xu, Wei Wei, Hongbin Li, Liyun Zhang, Yi Zhao, Xiaofei Shi, Yan Zhang, Xiaofeng Zeng, Xiaomei Leng   +10 more
doaj   +1 more source

Efficacy and safety of tocilizumab and baricitinib among patients hospitalized for COVID-19: a systematic review and meta-analysis

Frontiers in Pharmacology, 2023
Introduction: Tocilizumab and baricitinib are recommended treatment options for COVID-19 patients with hyperinflammatory response; however, there is a lack of systematic review directly evaluating their efficacy and safety.Objective: This review was ...
Jin Zhang, Jin Zhang, Xiongxiong Fan, Xiaoyu Zhang, Fengli Jiang, Yiping Wu, Beibei Yang, Xinghuan Li, Dong Liu, Dong Liu   +9 more
doaj   +1 more source

Combined Metformin and Baricitinib Therapy Attenuates Inflammation in STZ‐Induced Diabetic Rats via AMPK/JAK–STAT Pathway Crosstalk

Endocrinology, Diabetes & Metabolism
Background Chronic inflammation is a critical factor contributing to diabetes complications. Baricitinib inhibits JAK–STAT signalling, which can contribute to an anti‐inflammatory effect.
Mostafa Allahyari, AbdolJalal Marjani, Marie Saghaeian Jazi, Mehrdad Jahanshahi   +3 more
doaj   +1 more source

The association between systemic inflammation as measured by calprotectin and autoantibody load in rheumatoid arthritis

Arthritis &Rheumatology, Accepted Article.
Background Plasma calprotectin is a marker of neutrophil activity. Its relation to the clinical phenotype and autoantibodies in rheumatoid arthritis (RA) is only partly understood. We therefore aimed to investigate the association between calprotectin and clinical parameters, CRP, ESR, anti‐CCP2 and other anti‐modified protein autoantibodies (AMPAs) in
Caroline Grönwall, Linda Mathsson Alm, Helga Westerlind, Isabel Gehring, Nasim Ghasemzadeh, Niels Steen Krogh, Siri Lillegraven, Espen Haavardsholm, Martina Johannesson, Tore K. Kvien, Johan Rönnelid, Tue Wenzel Kragstrup, Bente Glintborg, Merete Lund Hetland, Hilde Berner Hammer, The Danish Rheumatologic Biobank Study Group, Swedish Rheumatology Quality Register Biobank Study Group(SRQb), Johan Askling, Oliver Hendricks, Estrid Høgdall, Dorte Vendelbo Jensen, Heidi Lausten Munk, Jens Kristian Pedersen, Torkell Ellingsen, Anne Gitte Loft, Ellen‐Margrethe Hauge, Salome Kristensen, Lene Dreyer, Asta Linauskas, Søren Jacobsen, Carl Turesson, Solbritt Rantapää Dahlqvist, Lena Björkman, Alf Kastbom, Eva Baecklund   +34 more
wiley   +1 more source

Outcomes of Tapering Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Multicenter Randomized Noninferiority Trial

Arthritis &Rheumatology, EarlyView.
Objective Evidence supporting tapering of biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) in patients with rheumatoid arthritis (RA) with sustained low disease activity (LDA) remains limited. We evaluated the efficacy and safety of a structured b/tsDMARD‐tapering strategy in patients with RA who had achieved sustained ...
Dong‐Jin Park, Sung‐Eun Choi, Ji‐Hyoun Kang, Jung‐Yoon Choe, Hye‐Soon Lee, So‐Young Bang, Yun‐Hong Cheon, Sang‐Il Lee, Mingyo Kim, Yoon‐Kyoung Sung, Soo‐Kyung Cho, Jae Hyun Jung, Sung Hae Chang, Sung Won Lee, Yeon‐Ah Lee, Seung‐Geun Lee, Hyun‐Sook Kim, Seung‐Ki Kwok, Seung‐Cheol Shim, Shin‐Seok Lee   +19 more
wiley   +1 more source

Real‐World Treatment Patterns and Characteristics of Patients Aged 15 Years and Older Treated With Baricitinib for Alopecia Areata in Japan

Dermatologic Therapy
Objective This study aimed to describe real‐world treatment patterns and clinical characteristics of Japanese patients with alopecia areata (AA), particularly focusing on those treated with baricitinib.
Kazutoshi Harada, Taisuke Kojima, Yasuhiro Miki, Yoshitaka Isaka, Yumiko Nishikawa, Hitoe Torisu-Itakura, Manabu Ohyama   +6 more
doaj   +1 more source

Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System

Frontiers in Immunology, 2018
The purpose of this study was to elucidate the mechanism of action of baricitinib on Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling, which involves in human innate and adaptive immune system.
Satoshi Kubo, Shingo Nakayamada, Kei Sakata, Kei Sakata, Yukihiro Kitanaga, Yukihiro Kitanaga, Xiaoxue Ma, Xiaoxue Ma, Seunghyun Lee, Akina Ishii, Akina Ishii, Kaoru Yamagata, Kazuhisa Nakano, Yoshiya Tanaka   +13 more
doaj   +1 more source